Nevro‘s patent involves systems for treating diseases using electrical stimulation. The method targets fast sodium channels and glial cells in patients by applying electrical therapy signals with frequencies ranging from 1.5 kHz to 100 kHz. The claim focuses on treating pain by changing the activity of glial cells in the spinal cord using specific frequency ranges. GlobalData’s report on Nevro gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Nevro, Neuromodulation implants was a key innovation area identified from patents. Nevro's grant share as of May 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating pain by changing glial cell activity
A recently granted patent (Publication Number: US11998744B1) discloses a method for treating pain in patients by targeting the activity of glial cells in the spinal cord. The method involves using a signal generator to deliver an electrical therapy signal to a neural population in the patient's spinal cord, resulting in changes in the glial cell activity. These changes can include downregulation of glial cell activity, reduction in the release of inflammatory substances, modulation of glial interaction with neuronal cells, and ultimately reducing chronic pain in the patient. The frequency, pulse width, and amplitude of the electrical therapy signal are carefully controlled to ensure effectiveness without causing paresthesia.
Furthermore, the patent also covers variations of the method, such as targeting specific regions of the spinal cord like the dorsal horn or dorsal column, and altering the expression of glial cells to reduce pain. By programming the signal generator to deliver the electrical therapy signal to the appropriate neural population, changes in glial cell expression can be achieved, leading to a decrease in pain sensation. The method outlined in the patent aims to provide a non-invasive and effective way to manage chronic pain by directly influencing the activity and expression of glial cells in the spinal cord, offering a promising approach for patients seeking alternative pain management strategies.
To know more about GlobalData’s detailed insights on Nevro, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
